HCW Biologics Inc.
HCWBNASDAQHealthcare● Active
$1.45
$-0.18(-11.04%)
Market Cap$3024477
P/E Ratio—
52W High$7.35
52W Low$0.25
HCW Biologics Inc. (HCWB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HCWB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
$0.37
Est. -$0.44 · +184.1%
Revenue
$0.01B
Est. $0.01B · -0.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
HCWB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 7, 2026 | -$0.33 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.44 | $0.37 | +184.1% | $0.01B | $0.01B | -0.2% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$0.84 | -$2.63 | -213.1% | $0.00B | $0.01B | -99.6% |
| ▼ Q4 FY2025 | Nov 14, 2025 | $1.58 | -$2.02 | -227.8% | $0.00B | $0.01B | -99.8% |
| ▼ Q3 FY2025 | Aug 18, 2025 | $1.80 | -$6.79 | -477.2% | $0.00B | $0.00B | -6.4% |
| — Q2 FY2025 | May 15, 2025 | — | -$0.05 | — | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 28, 2025 | $3.60 | -$3.20 | -188.9% | $0.00B | $0.01B | -94.4% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$5.20 | -$4.00 | +23.1% | $0.00B | — | — |
Q3 FY2026
Aug 7, 2026
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
$0.37
EPS Est.
-$0.44
EPS Surpr.
+184.1%
Revenue
$0.01B
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$2.63
EPS Est.
-$0.84
EPS Surpr.
-213.1%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$2.02
EPS Est.
$1.58
EPS Surpr.
-227.8%
Revenue
$0.00B
Q3 FY2025
Aug 18, 2025Miss
EPS Actual
-$6.79
EPS Est.
$1.80
EPS Surpr.
-477.2%
Revenue
$0.00B
Q2 FY2025
May 15, 2025
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2025
Mar 28, 2025Miss
EPS Actual
-$3.20
EPS Est.
$3.60
EPS Surpr.
-188.9%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$4.00
EPS Est.
-$5.20
EPS Surpr.
+23.1%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q3 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q2 FY2026 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q1 FY2026 | $-0.44 | $-0.44 | $-0.44 | 1 |
| Q4 FY2025 | $-0.84 | $-0.84 | $-0.84 | 1 |
| Q3 FY2025 | $1.58 | $1.58 | $1.58 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +184.1% | $0.35 | $0.34 | -3.55% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -213.1% | $0.36 | $0.36 | -0.25% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -227.8% | $2.49 | $3.00 | +20.48% |
| ▼ Q3 FY2025 | Aug 18, 2025 | -477.2% | $4.09 | $4.02 | -1.71% |
| — Q2 FY2025 | May 15, 2025 | — | $8.81 | $8.20 | -6.92% |
| ▼ Q1 FY2025 | Mar 28, 2025 | -188.9% | $12.10 | $12.00 | -0.83% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +23.1% | $12.40 | $12.36 | -0.32% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -122.2% | $24.42 | $23.20 | -5.00% |
Q2 FY2026-3.55%
Report Date
May 14, 2026
EPS Beat/Miss
+184.1%
Price Before
$0.35
Price After
$0.34
Q1 FY2026-0.25%
Report Date
Mar 31, 2026
EPS Beat/Miss
-213.1%
Price Before
$0.36
Price After
$0.36
Q4 FY2025+20.48%
Report Date
Nov 14, 2025
EPS Beat/Miss
-227.8%
Price Before
$2.49
Price After
$3.00
Q3 FY2025-1.71%
Report Date
Aug 18, 2025
EPS Beat/Miss
-477.2%
Price Before
$4.09
Price After
$4.02
Q2 FY2025-6.92%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$8.81
Price After
$8.20
Q1 FY2025-0.83%
Report Date
Mar 28, 2025
EPS Beat/Miss
-188.9%
Price Before
$12.10
Price After
$12.00
Q4 FY2024-0.32%
Report Date
Nov 14, 2024
EPS Beat/Miss
+23.1%
Price Before
$12.40
Price After
$12.36
Q3 FY2024-5.00%
Report Date
Aug 14, 2024
EPS Beat/Miss
-122.2%
Price Before
$24.42
Price After
$23.20
Avg Beat Reaction-1.93%
Avg Miss Reaction+2.54%
Beat Rate2 / 8 quarters
Largest Move+20.48% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HCWB ends December
HCW Biologics Inc. (HCWB) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $0.37 — beating the analyst consensus of $-0.44 by +184.1%. The next HCWB earnings date is expected around September 1, 2026.
Each quarter, investors track HCWB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HCWB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HCWB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HCWB earnings · 5 questionsHCW Biologics Inc.'s next earnings report is expected around September 1, 2026. HCWB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HCWB historically reports after market close (AMC).
HCWB earnings datewhen is HCWB earningsHCWB next earnings datewhen does HCWB report earningsHCWB earnings calendar
▸ Source: FMP · HCW Biologics Inc. SEC filings · US GAAP · HCW Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026